expand_moreexpand_less
Aeon
Al Jazeera
América Economía
Blitz
Buenos Aires Herald
Deutsche Welle
Dnevnik
E-International
Haaretz
Il Manifesto Global
Japan Today
Khaama PressMiddle East Monitor
New Eastern OutlookNikkei Asian ReviewOped Column
Pravda.sk
Project Syndicate
Psychology TodayRT.comSME.sk
South China Morning PostThe Asahi ShimbunThe DiplomatThe Japan NewsThe Japan Times
The Korea TimesThe Times of IsraelThe Times of Israel (Blogs)Večer
العين الإخبارية 
Toi StaffEmanuel FabianAgenciesJacob MagidJeremy SharonReutersLazar BermanCanaan LidorSam Sokol
Gideon LevyThe Japan News EditorialDavid HorovitzGianluca PacchianiJessica SteinbergCharlie Summers
Belen FernandezAmy SpiroAmérica EconomíaThe Asahi ShimbunGavriel FiskeAeon Video
Tarik Cyril AmarJeffrey SachsCathrin SchaerRenee Ghert-ZandMatt LebovicEhud OlmertSue SurkesRobert PhilpotCathryn J. Prince
Rami G KhouriRon KampeasJennifer Holleis
Dr Ramzy BaroudOdeh BisharatAndrew LapinBen KnightStuart WinerJordana HornLuke TressMichael Sfard
Mort LaitnerMikhael ManekinJacob GurvisUri MisgavYoana GonenRobert ZaretskyNadia CalviñoYvonne Ridley
Petra Lesjak Tušek
|
|
Naomi KresgeFortune |
The market for obesity treatments may soar above $80 billion by 2030 according to analysts.
The blockbuster drug from Novo Nordisk has a list price of about $1,350 per month in the US.
“These drugs are definitely an important tool, but they should not be seen as a solution to the problem,” says a WHO official who co-authored a...
login
who are we?
contact us
qosheapp
